SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : momo-T/FIF
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tom pope who wrote (3064)9/14/2005 1:20:14 PM
From: Icebrg  Read Replies (2) of 12215
 
Boronate at the MLNM YMB suggests:

My two cents
by: boronate 09/14/05 12:46 pm
Msg: 67543 of 67544

My opinion is that Celg will get on October 7 an approvable letter from the FDA, pending the Phase III trial to define the role of 5 mg starting dose. The committee was adamant on this point with a 13-2 no vote on the proposed starting dose. This will preclude Rev coming into the market for MDS for a long time. The marketing will the depend on the yet to be submitted NDA for myeloma.

Erik
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News